Ubrogepant

Ubrogepant
Clinical data
Other names	MK-1602
ATC code	none;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name (6S)-N-[(3S,5S,6R)-6-Methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide;
CAS Number	1374248-77-7;
PubChem CID	68748835;
ChemSpider	28536135;
UNII	AD0O8X2QJR;
KEGG	D10673;
ChEMBL	ChEMBL2364638;
CompTox Dashboard (EPA)	DTXSID00160178 ;
Chemical and physical data
Formula	C29H26F3N5O3
Molar mass	549.554 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)c2cc3c(nc2)C[C@@]4(C3)c5cccnc5NC4=O)c6ccccc6;
	InChI InChI=1S/C29H26F3N5O3/c1-16-20(17-6-3-2-4-7-17)11-22(26(39)37(16)15-29(30,31)32)35-25(38)19-10-18-12-28(13-23(18)34-14-19)21-8-5-9-33-24(21)36-27(28)40/h2-10,14,16,20,22H,11-13,15H2,1H3,(H,35,38)(H,33,36,40)/t16-,20-,22+,28+/m1/s1; Key:DDOOFTLHJSMHLN-ZQHRPCGSSA-N;

Ubrogepant is an experimental drug for the treatment of migraine. It is a small-molecule calcitonin gene-related peptide receptor antagonist.^[1]^[2]

References

^ Tfelt-Hansen, P; Olesen, J (April 2011). "Possible Site of Action of CGRP Antagonists in Migraine". Cephalalgia: An International Journal of Headache. 31 (6): 748–50. doi:10.1177/0333102411398403. PMID 21383046.
^ Spreitzer, H (22 May 2018). "Neue Wirkstoffe: Ubrogepant". Österreichische Apotheker-Zeitung (in German) (11/2018).

This analgesic-related article is a stub. You can help Wikipedia by expanding it.